Interleukin-2 (IL-2) as a consolidative treatment after autologous bone marrow transplantation for hematologic malignancies.

被引：0
|
作者：
Massumoto, C [1 ]
Ostronoff, M [1 ]
Macedo, MCMA [1 ]
ZAmbon, E [1 ]
Medeiros, RSS [1 ]
DorlhiacLlacer, PE [1 ]
Chamone, DAF [1 ]
Dulley, F [1 ]
机构：
[1] UNIV SAO PAULO,HEMOCTR SAO PAULO,FDN PRO SANGUE,BR-05508 SAO PAULO,BRAZIL
来源：
BLOOD | 1995年 / 86卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3817 / 3817
页数：1
相关论文
共 50 条
  • [41] CLINICAL AND IMMUNOLOGICAL EFFECTS OF CONTINUOUS INFUSION INTERLEUKIN-2 AFTER ALLOGENEIC AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION
    SOIFFER, R
    MURRAY, C
    RITZ, J
    CLINICAL RESEARCH, 1991, 39 (02): : A431 - A431
  • [42] Survival following interleukin-2 (IL-2) activated autologous PBSC transplantation and post transplant IL-2 therapy in women with breast cancer.
    Meehan, KR
    Verma, UN
    ArunKilic, B
    Frankel, SR
    Rajagopal, C
    Cahill, R
    Jensen, M
    Lippman, ME
    Mazumder, A
    BLOOD, 1996, 88 (10) : 497 - 497
  • [43] Early and prolonged (D1-86) administration of low dose interleukin 2 after autologous stem cell transplantation for hematologic malignancies.
    Stoppe, AM
    Vey, N
    Viret, F
    Fauchet, C
    Chabannon, C
    Camerlo, J
    Cappiello, M
    Blaise, D
    Maraninchi, D
    BONE MARROW TRANSPLANTATION, 1998, 21 : S104 - S104
  • [44] CLINICAL AND IMMUNOLOGICAL EFFECTS OF IL-2 IN NONHODGKINS LYMPHOMA PATIENTS AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION
    LAURIA, F
    RASPADORI, D
    ZINZANI, PL
    RONDELLI, D
    GHERLINZONI, F
    VENTURA, MA
    BENFENATI, D
    TURA, S
    BLOOD, 1993, 82 (10) : A145 - A145
  • [45] Adoptive immunotherapy with recombinant human IL-2 after autologous bone marrow transplantation for high risk neuroblastoma
    Prete, A
    Rondelli, R
    Locatelli, F
    Pierinelli, S
    Fagioli, F
    Messina, C
    Garaventa, A
    Pession, A
    BONE MARROW TRANSPLANTATION, 2004, 33 : S219 - S219
  • [46] SOLUBLE INTERLEUKIN-2 RECEPTORS IN PATIENTS AFTER BONE-MARROW TRANSPLANTATION
    SIEGERT, W
    JOSIMOVICALASEVIC, O
    SCHWERDTFEGER, R
    BAURMANN, H
    SCHMIDT, CA
    MUSCH, R
    SCHMID, HJ
    HARTMANN, R
    HENZE, G
    HUHN, D
    DIAMANTSTEIN, T
    BONE MARROW TRANSPLANTATION, 1990, 6 (02) : 97 - 101
  • [47] A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomas
    Vey, N
    Blaise, D
    Tiberghien, P
    Attal, M
    Pico, JL
    Reiffers, J
    Harrousseau, JL
    Fiere, D
    Tabilio, A
    Gabus, R
    Brandely, M
    Maraninchi, D
    LEUKEMIA & LYMPHOMA, 1996, 21 (1-2) : 107 - 114
  • [48] Bone marrow transfected with the IL-2 gene for reducing leukemic relapse following autologous bone marrow transplantation.
    Tam, YK
    Klingemann, HG
    BLOOD, 1997, 90 (10) : 4633 - 4633
  • [49] EFFECTS OF INTERLEUKIN-2 ON ENGRAFTMENT FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) IN DOGS
    SAMUEL, S
    NAGLER, A
    OR, R
    SLAVIN, S
    LEUKEMIA RESEARCH, 1992, 16 (10) : 967 - 972
  • [50] INTERLEUKIN-2 (IL-2) AND INTERLEUKIN-2 RECEPTOR (IL-2R) PRODUCTION IN SCHIZOPHRENIA
    ODONNELL, MD
    CATTS, SV
    WARD, PB
    WAKEFIELD, D
    LIEBERT, B
    MCCONAGHY, N
    SCHIZOPHRENIA RESEARCH, 1994, 11 (02) : 128 - 128
12345